Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 4Gastrointestinal 2Breast 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Genitourinary 1Dermatologic 1Classical hematology 1

Conditions

Pancreatic Neoplasms 154Stomach Neoplasms 23Neoplasms 18Neoplasm Metastasis 17Esophageal Neoplasms 16Esophageal Squamous Cell Carcinoma 12Cholangiocarcinoma 12Adenocarcinoma 11Breast Neoplasms 9Pancreatic Adenocarcinoma 8Colorectal Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Ovarian Neoplasms 7Carcinoma, Pancreatic Ductal 7Biliary Tract Neoplasms 7Lung Neoplasms 6Gallbladder Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Pancreatic Diseases 5Digestive System Neoplasms 5Urinary Bladder Neoplasms 4Triple Negative Breast Neoplasms 4Sarcoma 4Prostatic Neoplasms 4Endocrine Gland Neoplasms 4Digestive System Diseases 4Advanced Pancreatic Cancer 4Rectal Neoplasms 3Neoplasms, Glandular and Epithelial 3Neoplasms by Site 3

Interventions

Nivolumab 3Cyclophosphamide 3pembrolizumab 2fludarabine phosphate 2durvalumab 2Specimen Handling 2Polymerase Chain Reaction 2Leucovorin 2Interleukin-2 2Imatinib Mesylate 2Gemcitabine 2Fluorouracil 2Doxorubicin 2Dasatinib 2Capecitabine 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2venetoclax 1vactosertib 1trametinib 1tazemetostat 1ruxolitinib 1regorafenib 1ponatinib 1pertuzumab 1palbociclib 1olaparib 1neratinib 1motexafin gadolinium 1lorlatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hodgkin Disease × Albumin-Bound Paclitaxel × Gastrointestinal × Clear all
NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT01929941 2018-01-17

An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies

Incyte Corporation

Phase 1 Terminated
5 enrolled
BreastGastrointestinalLymphoid

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡